Personal data

Name: Csaba Bödör
Date of birth: June 7, 1982
Place of birth: Nitra
Nationality: Hungarian

 

Qualifications

  • DSc, Doctor of Academy of Hungarian Sciences (2021)
  • Habilitation (2021), Semmelweis University
  • Board-certified clinical biochemist (2021), Semmelweis University, Budapest, Hungary
  • MSc degree (2020): Healthcare Manager, Health Services Management Training Centre, Semmelweis University, Budapest, Hungary
  • PhD degree (2008): Molecular Oncology program, Doctoral School of Pathology, Semmelweis University, Budapest, Hungary
  • MSc degree (2005): Molecular biologist, specialization: immunology, Eötvös Loránd University of Natural Sciences, Budapest, Hungary

 

Positions

 

Field of interest

  • Molecular genomics and pathogenesis of lymphomas
  • Genomics, epigenetics
  • Personalised medicine, targeted therapy

 

Memberships

  • Elected board member of the Hungarian Society of Personalized Medicine (2020)
  • Representative of the Semmelweis University in the Eurolife international consortium (2019)
  • Elected member of the executive board of the Hungarian Society of Hematology and Transfusion (2013) and secretary (2017)
  • Member of the molecular diagnostic board of the EWOG-MDS international group (2017)
  • Founding member of the Molecular Pathology workgroup of the Hungarian Society of Personalized Medicine (2012)
  • European Hematology Association-EHA (2010)

 

Independent Grant Funding

  • Epigenetic model of Follicular Lymphoma, European Hematology Assocation (EHA) post-doctoral partner fellowship, 3 years (2010-2012); 105.000 EUR.
  • Aberrant epigenetic regulation in follicular lymphoma, Szent-Györgyi Albert post-doctoral scholarship, 1 year (2013.05-2014-05); 20.000 EUR.
  • Investigation of the genetic background of familial myelodysplastic syndromes (MDS) and acute myeloid leukaemias (AML), OTKA-PD grant, 2 years (2013.09-2015.09); 25.000 EUR
  • Personalised medicine in B-cell lymphomas (MTA Momentum grant of the Hungarian Academy of Sciences) (2015-2020); 300.000 EUR.
  • Liquid biopsy-based identification and monitoring of novel therapeutic targets in B-cell lymphomas. NKFIH-KH17 grant (2018-2019); 65.000 EUR
  • ERA-PERMED Human disease modelling of GATA2-related Myelodysplastic Syndromes and Acute Myeloid Leukemia (2019-2022). 1.000.000 EUR.
  • Liquid biopsy based genomic profiling and minimal residual disease detection in mature B-cell lymphomas. HCEMM Translational Research Group program (2021-2026).

 

Additional training

  • Exome sequencing and data analysis course: Imperial College London (January 2012)
  • Joint EBI-Wellcome Trust Summer school in bioinformatics, Cambridge, UK (2011)